Literature DB >> 28502413

Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.

Jake G Natalini1, Jeff J Swigris2, Julie Morisset1, Brett M Elicker3, Kirk D Jones4, Aryeh Fischer5, Harold R Collard1, Joyce S Lee6.   

Abstract

RATIONALE: Health-related quality of life (HRQL) is impaired among patients with interstitial lung disease (ILD). Little is understood about HRQL in specific subtypes of ILD.
OBJECTIVES: The aim of this study was to characterize and identify clinical determinants of HRQL among patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and compare them to patients with idiopathic pulmonary fibrosis (IPF).
METHODS: We identified patients with a diagnosis of RA-ILD and IPF from an ongoing longitudinal cohort of ILD patients. HRQL was measured at their baseline visit using the Short Form Health Survey (SF-36), versions 1 and 2. Regression models were used to characterize and understand the relationship between selected baseline clinical covariates, the physical component score (PCS) and mental component score (MCS) of the SF-36.
MEASUREMENTS AND MAIN RESULTS: RA-ILD patients (n = 50) were more likely to be younger and female compared to IPF patients (n = 50). After controlling for age and pulmonary function, RA-ILD patients had a lower HRQL compared to IPF patients, as measured by the PCS (P = 0.03), with significant differences in two of four PCS domains - bodily pain (P < 0.01) and general health (P = 0.01). Clinical covariates most strongly associated with a lower PCS in RA-ILD patients compared to IPF patients were the presence of joint pain or stiffness and dyspnea severity (P < 0.01). Mental and emotional health, as measured by the MCS, was similar between RA-ILD and IPF patients.
CONCLUSION: The physical components of HRQL appear worse in RA-ILD patients compared to IPF patients as measured by the PCS of the SF-36. Differences in the PCS of the SF-36 can be explained in part by dyspnea severity and joint symptoms among patients with RA-ILD.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Interstitial lung disease; Pain; Quality of life; Rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28502413      PMCID: PMC5486989          DOI: 10.1016/j.rmed.2017.04.002

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  20 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis.

Authors:  Molly Lubin; Hubert Chen; Brett Elicker; Kirk D Jones; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

4.  Assessment of health-related quality of life in patients with interstitial lung disease.

Authors:  J A Chang; J R Curtis; D L Patrick; G Raghu
Journal:  Chest       Date:  1999-11       Impact factor: 9.410

Review 5.  Outcome assessments in rheumatoid arthritis.

Authors:  Katarzyna Gilek-Seibert; Kara Prescott; Salahuddin Kazi
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

6.  Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego.

Authors:  E G Eakin; P M Resnikoff; L M Prewitt; A L Ries; R M Kaplan
Journal:  Chest       Date:  1998-03       Impact factor: 9.410

7.  Predictors of physical and mental health-related quality of life in patients with interstitial lung disease: a multifactorial analysis.

Authors:  Ana Cláudia Coelho; Marli Maria Knorst; Marcelo Basso Gazzana; Sérgio Saldanha Menna Barreto
Journal:  J Bras Pneumol       Date:  2010 Sep-Oct       Impact factor: 2.624

8.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.

Authors:  C Turesson; W M O'Fallon; C S Crowson; S E Gabriel; E L Matteson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

9.  Common Mechanisms of Dyspnea in Chronic Interstitial and Obstructive Lung Disorders.

Authors:  Azmy Faisal; Bader J Alghamdi; Casey E Ciavaglia; Amany F Elbehairy; Katherine A Webb; Josuel Ora; J Alberto Neder; Denis E O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2016-02-01       Impact factor: 21.405

Review 10.  Pulmonary manifestations of rheumatoid arthritis.

Authors:  L T Tanoue
Journal:  Clin Chest Med       Date:  1998-12       Impact factor: 2.878

View more
  9 in total

Review 1.  Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.

Authors:  Aryeh Fischer; Jörg Distler
Journal:  Clin Rheumatol       Date:  2019-08-19       Impact factor: 2.980

2.  Differentially expressed lncRNAs in peripheral blood mononuclear cells from middle-aged female patients with rheumatoid arthritis-associated interstitial lung disease.

Authors:  Wei Zhou; Juan Zheng; Min Yuan; Lindong Yuan; Xiaodong Jia; Huaxiang Liu
Journal:  Clin Rheumatol       Date:  2020-03-05       Impact factor: 2.980

3.  Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability.

Authors:  Atakan Topcu; H Hakan Mursaloglu; Yasemin Yalcinkaya; Sait Karakurt; Burcu Yagiz; Zeynep Alaca; Meryem Demir; Belkis Nihan Coskun; Ediz Dalkilic; Nevsun Inanc
Journal:  Clin Rheumatol       Date:  2021-04-03       Impact factor: 2.980

4.  Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the MUC5B Promoter Variant.

Authors:  Scott M Matson; Kevin D Deane; Anna L Peljto; Tami J Bang; Peter B Sachs; Avram D Walts; Christopher Collora; Shuyu Ye; M Kristen Demoruelle; Stephen M Humphries; David A Schwartz; Joyce S Lee
Journal:  Am J Respir Crit Care Med       Date:  2022-02-15       Impact factor: 30.528

5.  The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.

Authors:  Alex Diamantopoulos; Emily Wright; Katerina Vlahopoulou; Laura Cornic; Nils Schoof; Toby M Maher
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

6.  RA-ILD: does more detailed radiological classification add something to our knowledge of this condition?

Authors:  Paola Faverio; Meena Kalluri; Fabrizio Luppi; Giovanni Ferrara
Journal:  J Thorac Dis       Date:  2020-06       Impact factor: 2.895

7.  Pain is a common problem in patients with ILD.

Authors:  Qinxue Shen; Ting Guo; Min Song; Wei Guo; Yi Zhang; Wang Duan; Yating Peng; Shanshan Ni; Xiaoli Ouyang; Hong Peng
Journal:  Respir Res       Date:  2020-11-11

8.  Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases.

Authors:  Xue-Yan Yuan; Hui Zhang; Li-Ru Huang; Fan Zhang; Xiao-Wen Sheng; Ai Cui
Journal:  PLoS One       Date:  2020-07-29       Impact factor: 3.240

9.  Establishing content-validity of a disease-specific health-related quality of life instrument for patients with chronic hypersensitivity pneumonitis.

Authors:  Kerri I Aronson; Maha Ali; Evgeniya Reshetynak; Robert J Kaner; Fernando J Martinez; Monika M Safford; Laura C Pinheiro
Journal:  J Patient Rep Outcomes       Date:  2021-01-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.